NYSE:BHVNBiotechs
Biohaven (BHVN): Evaluating Valuation After New BHV-1510 Oncology Data at ESMO Immuno-Oncology Congress
Biohaven (BHVN) just put fresh oncology data in front of specialists at the ESMO Immuno Oncology Congress, sharing early results for its Trop2 antibody drug conjugate BHV 1510 combined with Regeneron’s cemiplimab.
See our latest analysis for Biohaven.
The BHV 1510 update lands after a volatile year, with a sharp 30 day share price return of 45.03% but a steep year to date share price decline and weak one year total shareholder return, signalling tentative momentum in a still high risk...